...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >The effects of mirtazapine on plasma lipid profiles in healthy subjects.
【24h】

The effects of mirtazapine on plasma lipid profiles in healthy subjects.

机译：米氮平对健康受试者血浆脂质谱的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The novel antidepressant mirtazapine has been linked to elevated random plasma total cholesterol (TC) levels. The purpose of this study was to evaluate in a more controlled and precise approach the putative effects of mirtazapine on plasma lipids. METHOD: In a double-blind design, 50 healthy subjects (30 women and 20 men) were randomized to receive either mirtazapine (N = 28) or placebo (N = 22) for a 4-week period. The study was conducted from June 1997 to September 1998. The initial dose for the mirtazapine group was 15 mg daily, which was increased to 30 mg daily at the beginning of the second week. Body weight and plasma lipoprotein profiles, including TC, low-density lipoproteins (LDL), high-density lipoproteins (HDL), and triglycerides, were determined at baseline and at weekly intervals throughout the study period. RESULTS: At baseline, there were no group differences in any of the measures. There was a statistically significant increase of 2.5% in mean body weight over the course ofthe study in the mirtazapine group that appeared to reach a plateau at 3 weeks, while no increase was observed in the placebo group. Mirtazapine subjects also showed significantly increased TC at week 4 (p =.016) and a transient rise in triglycerides that normalized by week 4. No significant changes in any of the other lipid parameters, including HDL, LDL, and TC/HDL ratios, were observed within either group. Changes in TC were significantly and positively correlated with changes in weight (p <.01). CONCLUSION: These results suggest that while mirtazapine may be associated with increased TC, it does not increase LDL levels or affect the ratio of TC to HDL.
机译：背景：新型抗抑郁药米氮平已与升高的随机血浆总胆固醇（TC）水平相关。这项研究的目的是以一种更加可控和精确的方法评估米氮平对血浆脂质的假定作用。方法：采用双盲设计，将50名健康受试者（30名女性和20名男性）随机分配接受米氮平（N = 28）或安慰剂（N = 22），持续4周。该研究于1997年6月至1998年9月进行。米氮平组的初始剂量为每天15 mg，在第二周开始时增加为每天30 mg。在整个研究期间的基线和每周间隔确定体重和血浆脂蛋白谱，包括TC，低密度脂蛋白（LDL），高密度脂蛋白（HDL）和甘油三酸酯。结果：在基线时，任何一项措施均无组间差异。在研究过程中，米氮平组的平均体重在统计学上显着增加了2.5％，在3周时似乎达到了稳定水平，而安慰剂组未观察到增加。 Mirtazapine受试者在第4周时还显示TC显着升高（p = .016），而在第4周时甘油三酯出现短暂升高，而在其他脂质参数（包括HDL，LDL和TC / HDL比）中均无显着变化，在两组中均观察到。 TC的变化与体重的变化显着正相关（p <.01）。结论：这些结果表明，米氮平可能与TC增加有关，但它不会增加LDL水平或影响TC与HDL的比率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号